Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
M JohnL WilliamsG NolanM BonnettA CastleyD NolanPublished in: HIV medicine (2024)
Long-acting cabotegravir plus rilpivirine was associated with very high adherence, maintenance of virological suppression, safety and treatment satisfaction in a diverse Australian clinic population, comparable to results of phase III randomized clinical trials. Individuals with vulnerability factors can achieve adherence to injections with individualized support. Long-acting therapies in this group can increase the subsequent engagement in clinical care.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- phase iii
- hiv infected
- human immunodeficiency virus
- open label
- hiv positive
- hiv aids
- clinical trial
- healthcare
- double blind
- palliative care
- social media
- primary care
- climate change
- placebo controlled
- glycemic control
- quality improvement
- metabolic syndrome
- platelet rich plasma
- pain management
- smoking cessation
- south africa
- replacement therapy